Participaciones del usuario wildness (4)

Participaciones del usuario wildness

wildness 23/07/12 18:12

Ha respondido al tema Farmas USA

Perdón que insista con STEM. ¿Estará dando señales de algo?

wildness 20/07/12 15:48

Ha respondido al tema Farmas USA

STEM parece que recupera. Alguien sabe algo de posibles rumores?

wildness 19/07/12 16:22

Ha respondido al tema Farmas USA

Muchas gracias por tu respuesta R2!

wildness 19/07/12 00:13

Ha respondido al tema Farmas USA

Saludos a todos. No suelo participar por mi falta de experiencia, pero me llama la atención un valor y me gustaría saber qué os parece? El valor en cuestión es BONE. De paso os felicito por este magnífico hilo! http://www.smallcapnetwork.com/Are-GNOM-HP-and-BONE-Worth-Renting-Here/s/via/1789/article/view/p/mid/3/id/188/

wildness 16/07/12 18:41

Ha respondido al tema Farmas USA

HGSI> Glaxo (GSK) Confirms Offer for Human Genome (HGSI), Deal Valued at $14.25/Share in Cash FREE Breaking News Alerts from StreetInsider.com! E-mail Address Top News Most Read Highlighted Citi (C) Beats Q2 Expectations of Loan and Deposit Growth, Transaction Services Performance Par Pharmaceutical (PRX) Hugs Buyout Price as it Could See Higher Bids Retail Sales Data Disappoints, but Shows Boon in Nonstore Sales (i.e. Online Shopping) U.S. 5-Year Bond Makes History (TLT) Glaxo (GSK) Confirms Offer for Human Genome (HGSI), Deal Valued at $14.25/Share in Cash Microsoft (MSFT) to Make Another Surprise Announcement, But What's Left? Nokia (NOK) Shares Volatile into Suprise Microsoft (MSFT) Announcement VIVUS (VVUS) Gets a Boost from Uber-Bullish Orexigen (OREX) Call Orexigen (OREX), Arena (ARNA) Stronger into Qnexa PDUFA MSG (MSG) Shares Under Pressure on Possible Departure of 'Lin'-spiring Superstar NCR's (NCR) POS Innovation, Cost Savings to Businesses Bode Well for Growth - Barron's Will Investors Heed Peer Warnings on Intel (INTC), Microsoft (MSFT) into Quarterly Results? VIVUS (VVUS) Gets a Boost from Uber-Bullish Orexigen (OREX) Call Fears About Effectiveness of Facebook's (FB) Ads Linger; Shares Remain Under Pressure Rick Sherlund Sees Possible Office 15 Announcement from Microsoft (MSFT) July 16, 2012 9:17 AM EDT GSK Hot Sheet Overall Analyst Rating: NEUTRAL ( Up) Dividend Yield: 4.8% EPS Growth %: -12.5% GlaxoSmithKline plc (NYSE: GSK) and Human Genome Sciences (NASDAQ: HGSI) today announced that the companies have entered into a definitive agreement under which GSK will acquire HGS for US$14.25 per share in cash.

wildness 04/07/12 22:37

Ha respondido al tema Farmas USA

Algo de Xoma: http://www.thestreet.com/story/11600724/2/5-stocks-under-10-set-to-soar.html